4142:TPE
Adimmune Corp
15,85 TWD
arrow_downward
-1,86%(-0,30) 1J
19 nov., 13:30:08 UTC+8 · TWD
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour 4142...
Ouverture
16,20 TWD
Élevé
16,25 TWD
Faible
15,70 TWD
Cap. boursière
6,81 Md
Vol. moyen
1,09 M
Volume
1,60 M
Ratio cours/bénéfice
91,85
+ haut sur 1 an
21,50 TWD
+ bas sur 1 an
15,65 TWD
BPA
0,17 TWD
Actions en circulation
235,29 M
Nombre d'employés
564
Ouverture
16,20 TWD
Élevé
16,25 TWD
Faible
15,70 TWD
Cap. boursière
6,81 Md
Vol. moyen
1,09 M
Volume
1,60 M
Ratio cours/bénéfice
91,85
+ haut sur 1 an
21,50 TWD
+ bas sur 1 an
15,65 TWD
BPA
0,17 TWD
Actions en circulation
235,29 M
Nombre d'employés
564
Articles
Sources : Web et partenaires du secteur de l'information
Traders Union
·
il y a 13 minutes
S&P 500 sees $2 trillion swing and 8.5 percent drop, Peter Tuchman notes
FXStreet
·
il y a 46 minutes
Dow Jones Industrial Average falls over 1,000 points as Anthropic IPO dominates
Investing.com
·
il y a 39 minutes
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.19%
ChartMill
·
il y a 2 heures
S&P 500 Top Movers: Gainers and Losers Today
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
À propos de Adimmune Corp